Marksans Pharma Limited (BOM: 524404)

Market Cap	119.75B
Revenue (ttm)	23.79B
Net Income (ttm)	3.47B
Shares Out	n/a
EPS (ttm)	7.65
PE Ratio	34.51
Forward PE	n/a
Dividend	0.60 (0.23%)
Ex-Dividend Date	Sep 17, 2024

Volume	40,402
Average Volume	73,436
Open	265.35
Previous Close	261.45
Day's Range	259.70 - 266.40
52-Week Range	126.05 - 358.50
Beta	n/a
RSI	38.24
Earnings Date	n/a

About Marksans Pharma

Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, upper respiratory, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamin...

• Industry: Pharmaceutical Preparations
• Founded: 1992
• Employees: 1,141
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524404

Financial Performance

In 2023, Marksans Pharma's revenue was 21.77 billion, an increase of 17.56% compared to the previous year's 18.52 billion. Earnings were 3.14 billion, an increase of 17.80%.